

## 02 Supplementary Material

Longitudinal study of SARS-CoV-2 infections in different employee groups of long distance train services in Germany

**Authors:**


HyoungJin Kim<sup>1,5</sup>, Robert Schultz-Heienbrok<sup>1\*</sup>, Markus Uhle<sup>1</sup>, Jenni Neubert<sup>1</sup>, Fabian Ball<sup>2</sup>, Matthes Metz<sup>3</sup>, Christian Gravert<sup>4</sup>

<sup>1</sup>Charité Research Organisation GmbH, Germany, <sup>2</sup>DB Fernverkehr AG, Germany, <sup>3</sup>Department of Biostatistics, GCP-Service International Ltd. & Co. KG, Germany, <sup>4</sup>Deutsche Bahn AG, Germany, <sup>5</sup>Janssen-Cilag GmbH, Germany


**Author for correspondence:**

Robert Schultz-Heienbrok


robert.schultz-heienbrok@charite-research.org




**Figure 2: IgG test results vs. reported fever (since March 2020) in the first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.




**Figure 3: IgG test results vs. reported coughing (since March 2020) in the first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.




**Figure 4: IgG test results vs. reported rhinitis (since March 2020) in first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.




**Figure 5: IgG test results vs. reported headache (since March 2020) in first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.



**Figure 6: IgG test results vs. reported limb pain (since March 2020) in first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.




**Figure 7: IgG test results vs. reported anosmia and ageusia (since March 2020) in first test series (June 2020).** Results are based on symptoms reported by participants in the questionnaire during the first test series.




**Figure 8: IgG test results vs. reported diabetes in first test series (June 2020).** Results are based on the symptom reported by participants in the questionnaire during the first test series.







**Figure 9: IgG test results vs. number of people living in same apartment (first test series: June 2020).** Results are based on answers of participants in the questionnaire during the first test series.



**Figure 10: IgG test results vs. children in same apartment in the first test series (June 2020).** Results are based on answers of participants in the questionnaire during the first test series.




**Figure 11: IgG test results vs. number of occupational contacts per week lasting more than 15 minutes (first test series: June 2020).** Results are based on answers of participants in the questionnaire during the first test series.




**With how many people do you spend more than 15 minutes per week in your free time (excluding household members)?**

IgG antibody test result      ■ Negative      ■ Positive


**Figure 12: IgG test results vs. number of contacts to people during free time per week lasting more than 15 minutes (first test series: June 2020).** Results are based on answers of participants in the questionnaire during the first test series.




**Figure 13: Comparison of employee groups vs. infection rate of participants in the second test series (October 2020).**



**Figure 14: Comparison of employee's residence at different study sites vs. infection rate in the second test series (October 2020).**




**Figure 15: Infection rate vs. reported fever (above 38°C) in second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.




**Figure 16: Infection rate vs. coughing (since March 2020) in second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.







**Figure 17: Infection rate vs. rhinitis (since March 2020) in second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.




**Figure 18: Infection rate vs. headache (since March 2020) in the second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.




**Figure 19: Infection rate vs. reported limb pain (since March 2020) in the second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.



**Figure 20: Infection rate vs. reported anosmia and ageusia (since March 2020) in the second test series (October 2020).** Results are based on the symptom reported by participants in the questionnaire during the second test series.




**Figure 21: Infection rate vs. reported diabetes (second test series: October 2020).** Results are based on answers of participants in the questionnaire during the second test series.




**With how many people do you live in the same apartment?**



**Figure 22: Infection rate vs. number of people in same apartment (second test series: October 2020).** Results are based on answers of participants in the questionnaire during the second test series.




**Figure 23: Infection rate vs. children in same apartment (second test series: October 2020).** Results are based on answers of participants in the questionnaire during the second test series.



**Figure 24: Infection rate vs. number of occupational contacts per week lasting more than 15 minutes (second test series: October 2020).** Results are based on answers of participants in the questionnaire during the second test series.





**Figure 25: Infection rate vs. number of contacts in free time per week lasting more than 15 minutes (second test series: October 2020).** Results are based on answers of participants in the questionnaire during the second test series